Table 2.

Main clinical evidences about antihyperglycemic effects of imeglimin.

Study population	Dosage	Duration of study	Effects	Ref.
33 patients with T2DM	1500 mg/12 h	7 days	Improved beta cell function, increased postprandial insulin release	[9]
59 patients with T2DM	2000 mg/day	4 weeks	Was as effective as metformin in reducing HbA1c, has more safety and tolerability than metformin	[14]
156 patients with T2DM	3000 mg/day	12 weeks	Decreased HbA1c, improved glycemic control	[16]
170 patients with T2DM	3000 mg/day	12 weeks	Reduced HbA1c and FBS, showed more safety than sitagliptin monotherapy	[17]
73 T2DM patients	1000-3000 mg/day	24 weeks	Improved plasma glucose control, showed good efficacy and safety especially in a dose of 2000 mg/day	[20]